Danaher (NYSE:DHR) Releases Earnings Results, Beats Expectations By $0.19 EPS

Danaher (NYSE:DHR) issued its quarterly earnings results on Wednesday. The conglomerate reported $2.11 earnings per share for the quarter, beating the consensus estimate of $1.92 by $0.19, FiscalAI reports. The firm had revenue of $6.55 billion during the quarter, compared to the consensus estimate of $6.56 billion. Danaher had a return on equity of 11.22% and a net margin of 16.91%. The company’s revenue was up 8.3% on a year-over-year basis. During the same period last year, the company earned $1.89 earnings per share.

Here are the key takeaways from Danaher’s conference call:

• Third-quarter results exceeded expectations, with sales of $6.6 billion, core revenue growth excluding respiratory revenue of 5.5%, adjusted operating margin of nearly 29%, and adjusted EPS of $2.11, up approximately 11.5% year over year.
• Danaher raised its full-year 2026 adjusted EPS guidance to $8.57-$8.62, reflecting third-quarter outperformance and expected double-digit EPS growth; management also cited strong free cash flow conversion of 128% year to date.
• Bioprocessing showed improving momentum, including mid-teens order growth led by upstream consumables and resins. Management remains confident in the segment’s long-term high-single-digit growth potential, although major U.S. reshoring projects are expected to contribute primarily from 2028 onward.
• New CEO Julie Sawyer Montgomery outlined priorities focused on commercial execution, innovation, talent, and disciplined capital allocation, including a more connected Danaher approach intended to drive share gains and accelerate profitable growth.
• Respiratory revenue remained a significant headwind, declining year over year to approximately $350 million in the quarter. Management expects respiratory revenue to be about $1.5 billion for 2026 and views that level as the starting point for 2027, with seasonal variability creating substantial uncertainty.

Danaher Stock Performance

DHR opened at $229.86 on Friday. The company’s 50 day moving average is $215.76 and its 200 day moving average is $197.12. The company has a current ratio of 1.65, a quick ratio of 1.25 and a debt-to-equity ratio of 0.48. The company has a market cap of $161.59 billion, a price-to-earnings ratio of 40.83, a PEG ratio of 2.95 and a beta of 0.76. Danaher has a 12-month low of $160.93 and a 12-month high of $242.80.

Danaher Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be issued a $0.40 dividend. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $1.60 dividend on an annualized basis and a dividend yield of 0.7%. Danaher’s dividend payout ratio (DPR) is presently 28.42%.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the stock. UBS Group reiterated a “buy” rating and issued a $260.00 price target on shares of Danaher in a research note on Thursday. JPMorgan Chase & Co. raised their price objective on shares of Danaher from $250.00 to $270.00 and gave the company an “overweight” rating in a research note on Thursday. Barclays lifted their target price on shares of Danaher from $255.00 to $260.00 and gave the stock an “overweight” rating in a report on Thursday. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and issued a $240.00 target price on shares of Danaher in a research note on Wednesday, July 22nd. Finally, The Goldman Sachs Group reiterated a “buy” rating and issued a $275.00 target price on shares of Danaher in a research note on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have issued a Hold rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $242.91.

More Danaher News

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Danaher reported third-quarter adjusted earnings of $2.11 per share, ahead of the $1.92 analyst consensus, while revenue reached approximately $6.55 billion. Profitability benefited from margin expansion and stronger Biotechnology performance. Danaher Beats Profit Estimates, Raises Outlook as Customer Demand Improves
• Positive Sentiment: Management raised its 2026 adjusted EPS outlook to $8.57-$8.62, citing improving customer demand and steady biopharmaceutical activity. Biotechnology orders grew at a mid-teens rate, supporting expectations for continued recovery. Danaher: 3 Key Takeaways for Long-Term Investors
• Positive Sentiment: Several analysts raised their price targets after the results. TD Cowen and JPMorgan lifted targets to $270, while Goldman Sachs increased its target to $275; the revisions indicate analysts see upside from improving execution, margins and Danaher’s AI strategy. Danaher Analysts Raise Their Forecasts Following Better-Than-Expected Q3 Earnings
• Neutral Sentiment: New CEO Julie Montgomery emphasized improved execution, innovation and the company’s “building blocks” for AI-enabled drug discovery. The strategy could create longer-term growth, but investors may wait for evidence that these initiatives translate into stronger operating results. Danaher says it has building blocks for AI drug discovery growth
• Negative Sentiment: Revenue was broadly in line but slightly below some estimates, and declines in respiratory diagnostics sales remained a concern despite the contribution from the Masimo acquisition. Danaher’s Masimo acquisition offsets drops in respiratory diagnostic sales
• Negative Sentiment: Analysts and management flagged tariffs and a cautious 2027 setup, while the CEO transition increases execution risk. With DHR trading at a relatively high valuation, investors appear to be taking profits despite the earnings beat and raised 2026 guidance. Danaher Posts First Earnings Under New CEO

About Danaher

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops products, services and solutions for the life sciences, biotechnology and diagnostics markets. Its offerings help researchers, pharmaceutical and biotechnology companies, healthcare providers and other organizations conduct scientific research, develop and manufacture medicines, and diagnose disease.

The company operates through businesses that provide bioprocessing equipment and technologies, laboratory instruments, consumables, analytical tools and clinical diagnostic systems.